Article tools
Author information
Published in Volume 101, Issue 4 (February 15,1998)
J. Clin. Invest. 101(4): 819-826 (1998). doi:10.1172/JCI1578.
Copyright © 1998, The American Society for Clinical Investigation.

Research Article

Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues.

T Takano, C B Clish, K Gronert, N Petasis and C N Serhan

Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

Published February 15, 1998

Neutrophil (PMN) activation is critical in inflammation and reperfusion injury, suggesting that PMN-directed therapies may be of clinical use. Here, leukotriene B4 (LTB4)-induced PMN influx in ear skin was equivalent between 5-lipoxygenase knockout and wild-type mice. To explore actions of lipoxin (LX) in PMN-mediated tissue injury, we prepared several novel LX stable analogues, including analogues of LXA4 and aspirin-triggered 15-epi-LXA4 as well as LXB4, and examined their impact in PMN infiltration and vascular permeability. Each applied topically to mouse ears inhibited dramatically PMN-mediated increases in vascular permeability (IC50 range of 13-26 nmol) with a rank order of 15(R/S)-methyl-LXA4 > 16-para-fluoro-phenoxy-LXA4 approximately 5(S)-methyl-LXB4 >/= 16-phenoxy-LXA4 > 5(R)-methyl-LXB4. These LX mimetics were as potent as an LTB4 receptor antagonist, yet results from microphysiometry with mouse leukocytes indicated that they do not act as LTB4 receptor level antagonists. In addition, within 24 h of delivery, > 90% were cleared from ear biopsies. Neither IL-8, FMLP, C5a, LTD4, nor platelet-activating factor act topically to promote PMN influx. When applied with LTB4, PGE2 enhanced sharply both infiltration and vascular permeability, which were inhibited by a fluorinated stable analogue of aspirin-triggered LX. These results indicate that mimetics of LXs and aspirin-triggered 15-epi-LXA4 are topically active in this model and are potent inhibitors of both PMN infiltration and PMN-mediated vascular injury.

This article Copyright © 1998, The American Society for Clinical Investigation.

Articles that cite
this article:

Resolvins and protectins: mediating solutions to inflammation
Payal Kohli, Bruce D Levy
Br J Pharmacol [CrossRef]

Functional polymorphism in ALOX15 results in increased allele-specific transcription in macrophages through binding of the transcription factor SPI1
Jonas Wittwer, Jacqueline Marti-jaun, Martin Hersberger
Hum Mutat 27(1):78. [CrossRef]

Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin
Stefano Fiorucci, Eleonora Distrutti, Andrea Mencarelli, Antonio Morelli, Stefan A Laufor, Giuseppe Cirino, John L Wallace
Br J Pharmacol 139(7):1351. [CrossRef]

Lipoxin and Aspirin-Triggered 15-epi-Lipoxin Cellular Interactions Anti-Inflammatory Lipid Mediators
Clary B. Clish, Charles N. Serhan, Tomoko Takano, Karsten Gronert, Nan Chiang
cclm 37(3):299. [CrossRef]

A novel rat lipoxin A4 receptor that is conserved in structure and function
Nan Chiang, Tomoko Takano, Makoto Arita, Shiro Watanabe, Charles N Serhan
Br J Pharmacol 139(1):89. [CrossRef]

Anti-Inflammatory and Proresolving Lipid Mediators
Charles N. Serhan, Stephanie Yacoubian, Rong Yang
Annu Rev Pathol Mech Dis 3(1):279. [CrossRef]

Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways
Charles N. Serhan
annu rev immunol 25(1):101. [CrossRef]

Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion
Nan Chiang, Karsten Gronert, Clary B. Clish, Jennifer A. O’brien, Mason W. Freeman, Charles N. Serhan
J Clin Invest 104(3):309. [CrossRef]

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Charles N. Serhan, Nan Chiang, Thomas E. Van dyke
Nat Rev Immunol 8(5):349. [CrossRef]

Physiological roles for ecto-5′-nucleotidase (CD73)
Sean P. Colgan, Holger K. Eltzschig, Tobias Eckle, Linda F. Thompson
Purinergic Signal 2(2):351. [CrossRef]

The Management of Inflammation in Periodontal Disease
Thomas E. Van dyke
J Periodontol 79(8s):1601. [CrossRef]

Controlling the Resolution of Acute Inflammation: A New Genus of Dual Anti-Inflammatory and Proresolving Mediators
Charles N. Serhan
J Periodontol 79(8s):1520. [CrossRef]

Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog
Niamh E. Kieran, Peter P. Doran, Susan B. Connolly, Marie-Claire Greenan, Debra F. Higgins, Martin Leonard, Catherine Godson, Cormac T. Taylor, Anna Henger, Matthias Kretzler
Kidney Int 64(2):480. [CrossRef]

Interactions Between Lipoxin A4, the Stable Analogue 16-phenoxy-lipoxin A4 and Leukotriene B4 in Cytokine Generation by Human Monocytes
P. Andersson, C. N. Serhan, N. A. Petasis, J. Palmblad
Scand J Immunol 60(3):249. [CrossRef]

Lipoxins: Potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease
Niamh E. Kieran, Paola Maderna, Catherine Godson
Kidney Int 65(4):1145. [CrossRef]

Resolution of inflammation: the beginning programs the end
Charles N Serhan, John Savill
Nat Immunol 6(12):1191. [CrossRef]

Dynamic purine signaling and metabolism during neutrophil–endothelial interactions
Thomas Weissmuller, Holger K. Eltzschig, Sean P. Colgan
Purinergic Signal 1(3):229. [CrossRef]

New mechanism for an old drug Aspirin triggers anti-inflammatory lipid mediators with gender implications
Nan Chiang, Charles N. Serhan
COMP 32(3):150. [CrossRef]

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus
C N Serhan, N Chiang
Br J Pharmacol 153(s1):S200. [CrossRef]

Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration
Gerard Bannenberg, Rose-Laure Moussignac, Karsten Gronert, Pallavi R Devchand, Birgitta A Schmidt, William J Guilford, John G Bauman, Babu Subramanyam, H Daniel perez, John F Parkinson
Br J Pharmacol 143(1):43. [CrossRef]